Copy of newspaper publication in relation to the financial results for the quarter and year ended March 31, 2026
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Solara Active Pharma Sciences published its Q4 FY26 and full year FY26 financial results (audited for annual, unaudited for quarterly). Standalone total income for Q4 FY26 was Rs. 387.29 Cr vs Rs. 273.01 Cr in Q4 FY25, showing strong growth. Full year standalone income reached Rs. 1,368.98 Cr vs Rs. 1,283.76 Cr in FY25. Net profit after tax for the full year on consolidated basis was Rs. 152.53 Cr (vs Rs. 27.96 Cr in prior year, partly due to discontinued operations). EPS for FY26 on consolidated basis was Rs. 97.84 per share (face value Rs. 2). The company also raised Rs. 312.79 Cr via a rights issue (target Rs. 449.95 Cr) and issued bonus shares in 2:1 ratio in September 2025.
Revenue growth is positive but Q4 standalone net profit of Rs. 8.74 Cr was lower than Q3 (Rs. 349 Cr revenue but only Rs. 8.74 Cr profit). The full year earnings per share of Rs. 97.84 is strong, reflecting the bonus share adjustment and improved profitability.